The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase 2 study of nivolumab (nivo) plus either standard or reduced dose bevacizumab (bev) in recurrent glioblastoma (rGBM).
 
Manmeet Singh Ahluwalia
Stock and Other Ownership Interests - CytoDyn; doctible; MimiVax
Honoraria - Elsevier; Peerview; Prime Education; Prime Oncology
Consulting or Advisory Role - Abbvie; Apollomics; Bayer; Celularity; Flatiron Health; FORMA Therapeutics; GlaxoSmithKline; InSightec; KIYATEC; Novocure; Nuvation Bio; Tocagen; Varian Medical Systems
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); MimiVax (Inst); Novartis (Inst); Novocure (Inst); Pharmacyclics (Inst)
 
Yasmeen Rauf
No Relationships to Disclose
 
Hong Li
No Relationships to Disclose
 
Patrick Y. Wen
Consulting or Advisory Role - Agios; AstraZeneca; Bayer; Blue Earth Diagnostics; Deciphera; deciphera; ElevateBio; Immunomic Therapeutics; Imvax; Integral Health; Karyopharm Therapeutics; KIYATEC; Puma Biotechnology; QED Therapeutics; Taiho Pharmaceutical; Taiho Pharmaceutical; Tocagen; Vascular Biogenics; VBI Vaccines; Voyager Therapeutics
Speakers' Bureau - Merck; Prime Oncology
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Celgene (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Oncoceutics (Inst); Puma Biotechnology (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)
 
David M. Peereboom
Honoraria - Elsevier
Consulting or Advisory Role - Orbus Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Mylan (Inst); Neonc Technologies (Inst); Novartis (Inst); Orbus Therapeutics (Inst); Pfizer (Inst); Stemline Therapeutics (Inst)
Travel, Accommodations, Expenses - Stemline Therapeutics
 
David A. Reardon
Honoraria - Advantagene; Agenus; Bayer; Bristol-Myers Squibb; DelMar Pharmaceuticals; EMD Serono; Imvax; Medicenna; Merck; Merck KGaA; Novocure; Oncorus; Regeneron; Sumitono Dainippon Pharma; Taiho Pharmaceutical
Consulting or Advisory Role - Advantagene; Agenus; Bayer; Bristol-Myers Squibb; Delmar Pharmaceuticals; EMD Serono; Imvax; Medicenna; Merck; Merck KGaA; Novocure; Oncorus; Regeneron; Taiho Pharmaceutical
Research Funding - Acerta Pharma (Inst); Agenus (Inst); Celldex (Inst); EMD Serono (Inst); Incyte (Inst); Omniox